Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | RAC1 | P63000 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3316173 | 0.99 | KDM4E (0.62) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL7822004 | 0.87 | KDM4E (0.60) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL7822956 | 0.81 | KDM4E (0.83) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL3321880 | 0.78 | KDM4E (0.80) | KDM4EMAPTNPC1RAB9AMEN1 | |
| Graveolinine SCHEMBL25286396 | 0.77 | KDM4E (0.66) | KDM4EMAPTNPC1RAB9AMEN1 | |
| Graveolinine SCHEMBL29411843 | 0.77 | KDM4E (0.66) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL3324961 | 0.76 | KDM4E (1.00) | KDM4EMAPTNPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL3318461 | 0.76 | KDM4E (0.78) | KDM4EMAPTNPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL3318463 | 0.76 | KDM4E (0.78) | KDM4EMAPTNPC1RAB9AMEN1 | |
| SCHEMBL3320461 | 0.76 | RAC1 (1.00) | KDM4EMAPTNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888346-B1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | UNIV RUTGERS (US) | 2001-06-06 | — | — | EP | claimed |
| EP-2185521-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | Exonhit Therapeutics SA (FR) | 2010-05-19 | — | — | EP | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
| EP-0888346-B1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | UNIV RUTGERS (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-0888346-A1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997029106-A1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | RAC1, RAC2, RAC3 | KDM4E 3958/4885MAPT 2679/4885NPC1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.